Sponsors / MGNX
MGNX

MacroGenics

Company identity has not yet been verified

See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.

Follow company
10Trials in this database
6Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes MellitusNCT00385697MacroGenicsPhase 2, Phase 3Completed2010-06Actual
Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic CancerNCT00625586MacroGenicsPhase 2Terminated2009-01-21Actual
Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes MellitusNCT00920582MacroGenicsPhase 3Terminated2012-04Actual
Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast CancerNCT01828021MacroGenicsPhase 2Completed2016-12-07Actual
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerNCT02492711MacroGenicsPhase 3Completed2021-08-11Actual
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerNCT04082364MacroGenicsPhase 2, Phase 3Completed2024-01-15Actual
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck CancerNCT04634825MacroGenicsPhase 2Terminated2022-07-29Actual
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsNCT05551117MacroGenicsPhase 2Terminated2024-07-04Actual
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate CancerNCT05848011MacroGenicsPhase 2Completed2026-02-19Actual
A Study of Lorigerlimab in Participants With Advanced Solid TumorsNCT06730347MacroGenicsPhase 2Recruiting2027-07Estimated

Latest recorded trial changes

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

NCT05551117 · MacroGenics

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Part 1: Radiographic Progression Free Survival (rPFS) as Determined by the Investigator; measure: Part 2: Objective Response Rate (ORR) Per Investigator Assessment of Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 Criteria

+ Updated value

measure: Part 1: Six-month Radiographic Progression Free Survival (rPFS) as Determined by the Investigator; measure: Part 2: Objective Response Rate (ORR) Per Investigator Assessment of Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 Criteria

Check registry source · The saved outcome text may be shortened. Check the source for full wording.